Drugs Made In America Acquisition Corp. Rights
DMAAR
NASDAQ Global Select0.12
USD
+0.00
- -
Drugs Made In America Acquisition Corp. Rights
DMAAR
(NASDAQ Global Select)
Recent
price
0.12
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- Drugs Made In America Acquisition Corp. Rights (DMAAR) represents the publicly traded rights of Drugs Made In America Acquisition Corp., a blank check company incorporated in 2024 and headquartered in Fort Lauderdale, Florida, that seeks to effect a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization, or similar business combination with one or more businesses, with a primary focus on the pharmaceutical industry to support domestic manufacturing of critical drugs and reduce U.S. reliance on foreign production. The company offers no current products or services beyond its special purpose acquisition structure, including ordinary shares (DMAA), units (DMAAU), and detachable rights (DMAAR) listed on Nasdaq; it targets high-growth entities in pharmaceuticals, biotechnology, drug development, manufacturing, and distribution, particularly those emphasizing U.S.-based operations and supply chain resilience. Recent developments include the closing of its $200 million initial public offering in early 2025 priced at $10 per unit, the full exercise of the IPO over-allotment option, the announcement of an advisory team, and the separate trading of ordinary shares and rights commencing February 25, 2025.